Stephens Reiterates Overweight Rating for MaxCyte (NASDAQ:MX

Stephens reaffirmed their overweight rating on shares of MaxCyte (NASDAQ:MXCT – Free Report) in a report published on Tuesday, Benzinga reports. The firm currently has a $11.00 price target on the stock. Several other equities analysts have also recently weighed in on the company. BTIG Research lowered their price target on MaxCyte from $10.00 to […]

Related Keywords

China , United States , William Blair , China Universal Asset Management Co , Financial Services Group Inc , Maxcyte Inc , Nisa Investment Advisors , Victory Capital Management Inc , Johnson Investment Counsel Inc , Free Report , Get Free Report , Services Group , Capital Management , Investment Counsel , Investment Advisors , China Universal Asset Management , Universal Asset Management , Maxcyte Daily , Maxcyte , Nasdaq Mxct , Mxct , Medical , Reiterated Rating , Stephens ,